Editing Basiliximab (section)

{{Short description|Pharmaceutical drug}}
{{Use dmy dates|date=March 2023}}
{{Infobox drug
| Verifiedfields = changed
| verifiedrevid = 459525440
| type = mab
| image =
| width =
| alt =
| caption =

<!-- Monoclonal antibody data -->
| mab_type = mab
| source = xi/o
| target = [[CD25]]

<!-- Clinical data -->
| pronounce =
| tradename = Simulect
| Drugs.com = {{drugs.com|monograph|basiliximab}}
| MedlinePlus = a612013
| licence_EU = yes
| DailyMedID = Basiliximab
| pregnancy_AU = D
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = [[Intravenous]]
| class = [[Immunosuppressants]]
| ATCvet =
| ATC_prefix = L04
| ATC_suffix = AC02
| ATC_supplemental =
| biosimilars =

<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Simulect FDA label">{{cite web | title=Simulect- basiliximab injection, powder, for solution | website=DailyMed | date=6 October 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af01887-b69d-444b-91ed-ebfe12784440 | access-date=27 February 2023 | archive-date=6 October 2022 | archive-url=https://web.archive.org/web/20221006113950/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af01887-b69d-444b-91ed-ebfe12784440 | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Simulect EPAR">{{cite web | title=Simulect EPAR | website=European Medicines Agency | date=31 October 2009 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/simulect | access-date=27 February 2023 | archive-date=11 January 2022 | archive-url=https://web.archive.org/web/20220111081038/https://www.ema.europa.eu/en/medicines/human/EPAR/simulect | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Rx-only

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life = 7.2 days
| duration_of_action =
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 179045-86-4
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00074
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9927MT646M
| KEGG = D03058
| ChEBI =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201439
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =

<!-- Chemical and physical data -->
| C=6378 | H=9844 | N=1698 | O=1997 | S=48
}}

'''Basiliximab''', sold under the brand name '''Simulect''', is a [[monoclonal antibody]] used to prevent [[Transplant rejection|rejection]] in [[kidney]] transplants.<ref name="Simulect FDA label" /><ref name="Simulect EPAR" /> It is a [[Chimera (genetics)|chimeric]] mouse-human monoclonal [[antibody]] to the α chain ([[CD25]]) of the [[IL-2 receptor]] of [[T cells]].<ref name="Simulect FDA label" /> It is used in combination with other medicines used to prevent organ rejection.<ref name="Simulect FDA label" /><ref name="Simulect EPAR" />

The most common side effects (seen in more than 20% of patients) include constipation, urinary tract infections (infection of the structures that carry urine), pain, nausea (feeling sick), peripheral oedema (swelling), hypertension (high blood pressure), anemia (low red blood cell counts), headache, hyperkalaemia (high blood potassium levels), hypercholesterolaemia (high blood cholesterol levels), surgical wound complication, weight increase, increased serum creatinine (a marker of kidney problems), hypophosphataemia (low blood phosphate levels), diarrhea and upper respiratory tract infection (colds).<ref name="Simulect EPAR" />

Basiliximab was approved for medical use in the United States and in the European Union in 1998.<ref name="Simulect FDA label" /><ref name="Simulect EPAR" /><ref>{{cite web | title=Basiliximab Product Approval Information - Licensing Action | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=20 February 2009 | url=https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093359.htm | archive-url=https://web.archive.org/web/20170113111552/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093359.htm | archive-date=13 January 2017 | url-status=dead | access-date=27 February 2023}}</ref>